Research programme: ASK1 inhibitors - Calchan
Latest Information Update: 01 Feb 2016
At a glance
- Originator Calchan
- Mechanism of Action MAP kinase kinase kinase 5 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Pain
Most Recent Events
- 11 May 2015 Preclinical trials in Inflammation in United Kingdom (PO)
- 11 May 2015 Preclinical trials in Pain in United Kingdom (PO)